PHARMACEUTICAL COMPOSITION CONTAINING DUSP5 AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING BONE METABOLIC DISEASES

The present invention relates to a pharmaceutical composition for preventing or treating bone metabolic diseases and a pharmaceutical composition for preventing or treating STAT3-mediated diseases, which contain DUSP5 as an active ingredient, and to a method for inhibiting STAT3 activity using DUSP5. The present invention can be favorably used as a novel therapeutic agent capable of treating bone metabolic diseases and STAT3-mediated diseases since DUSP5 can effectively inhibit expression or activity of RANKL, RANK, NFATc1, and TRAP, which are associated with differentiation of osteoclasts; can simultaneously inhibit or reduce activity of Th17 and promote or increase activity of regulatory T cells (Treg); and can inhibit activity of STAT3 through the inhibition of phosphorylation of STAT3. La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de maladies métaboliques osseuses et une composition pharmaceutique pour la prévention ou le traitement de maladies médiées par STAT3, qui contiennent DUSP5 en tant que substance active, et un procédé pour inhiber l'activité STAT3 au moyen de DUSP5. La présente invention peut être avantageusement utilisée en tant que nouvel agent thérapeutique capable de traiter des maladies métaboliques osseuses et des maladies médiées par STAT3 étant donné que DUSP5 peut inhiber efficacement l'expression de l'activité de RANKL, RANK, NFATc1, et TRAP, qui sont associés à la différenciation des ostéoclastes ; peut simultanément inhiber ou réduire l'activité de Th17 et favoriser ou augmenter l'activité de lymphocytes T régulateurs (Treg) ; et peut inhiber l'activité de STAT3 par l'intermédiaire de l'inhibition de la phosphorylation de STAT3. 본 발명은 DUSP5를 유효성분으로 모두 포함하는 골대사성 질환의 예방 또는 치료용 약학적 조성물, STAT3 매개 질환의 예방 또는 치료용 약학적 조성물 및 DUSP5을 이용한 STAT3의 활성 억제 방법에 관한 것으로, 본 발명은 DUSP5는 파골세포 분화와 관련된 RANKL, RANK, NFATc1 및 TRAP의 발현 또는 활성을 효과적으로 억제할 수 있고, Th17의 활성을 억제 또는 감소시키고 조절 T 세포(Regulatory T cell: Treg)의 활성을 촉진 또는 증가시키는 작용이 동시에 가능하며, STAT3의 인산화 억제를 통해 STAT3의 활성을 억제할 수 있어, 골대사성 질환 및 STAT3 매개로 인한 질환을 치료할 수 있는 새로운 치료제로서 유용하게 활용 가능할 것이다.